Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

Bevacizumab 76Fluorouracil 56Cetuximab 47Leucovorin 44Oxaliplatin 43pembrolizumab 35Irinotecan 34Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 18trifluridine tipiracil drug combination 16Nivolumab 15Blood Specimen Collection 15Panitumumab 14regorafenib 13Magnetic Resonance Spectroscopy 13Trifluridine 12Standard of Care 12Gemcitabine 12Biopsy 12Cisplatin 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 9tislelizumab 8Trastuzumab 8Cyclophosphamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × CX 5461 × Clear all
NCT07147231 2026-05-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
86 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡